Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00422656 · ClinicalTrials.gov registry record · Phase 2
Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT00422656 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 37 participants.
The verdict
NCT00422656, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
Waldenström's Macroglobulinemia (lymphoplasmacytic lymphoma, WM) remains incurable with limited therapeutic options and notably absent FDA approved therapy with any WM indication. Therefore, there is a need to identify new therapeutic agents for WM patients both in the upfront and relapsed/refractory setting. The purpose of this research study is to assess the efficacy of perifosine in patients with relapsed or refractory WM.
Interventions
- DRUG Perifosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2006-09 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00422656
The ClinicalTrials.gov registry entry for NCT00422656 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Perifosine is the first listed.
NCT00422656 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00422656 about?
NCT00422656 is a clinical study titled "Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia". Waldenström's Macroglobulinemia (lymphoplasmacytic lymphoma, WM) remains incurable with limited therapeutic options and notably absent FDA approved therapy with any WM indication. Therefore, there is a need to identify new therapeutic agents for WM patients both in the upfront and relapsed/refractor...
What is the current status of trial NCT00422656?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2006-09. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00422656?
The interventions under investigation include: Perifosine (DRUG).
Who is sponsoring clinical trial NCT00422656?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.